Vertex Pharmaceuticals Incorporated (VRTX)
Healthcare · Biotechnology · Data as of 2026-10-22
Bottom line
VRTX is trading at a premium to its history, in the middle of its recent price range, and recent volume shows no clear direction. The picture is mixed, so it may be worth watching rather than acting on. Past patterns are not a guarantee of future results.
Valuation — Trading at a premium (Red)
VRTX trades at 30× earnings, above its own 5-year average of 24× and roughly in line with similar healthcare companies we track (28×, 53 peers). Investors are currently paying more per dollar of earnings than usual. Its free-cash-flow yield is about 2.9%. Its current multiple sits around the 75th percentile of its own last five years — toward the high end of its own range.
Price zones — In the middle of its recent range (Yellow)
At $535.17, the stock sits between its recent support and resistance levels. Over the past year VRTX has traded between $403.16 and $560.25; its historical support zone sits near $522.56 and resistance near $560.25. It is above both its 50- and 200-day averages, which has historically signalled an uptrend.
52-week range $403.16–$560.25 · 50-day average $522.56 · 200-day average $477.17
Money flow — No clear direction (Yellow)
Buying and selling volume in VRTX have been fairly balanced recently, with no strong accumulation or distribution pattern. Volume on up days has been about 1.4× volume on down days over the last 30 sessions.
Dividends & company facts
VRTX doesn't pay a dividend, but it bought back $1.9 billion of its shares in fiscal 2025, about 1.4% of its market value. Its share count fell 1.2% over the past year and 2.0% over five.
- Buybacks
- 1.45% (fiscal 2025)
- Shares, past year
- -1.2%
- Revenue, 12 months
- $12.6B
- Profit, 12 months
- $4.4B
- Employees
- 6,400
- CEO
- Reshma Kewalramani
- Headquarters
- Boston, MA
- Listed since
- 1991 · NASDAQ
About the company
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation.
Related stocks
一句话结论
VRTX 相对自身历史处于溢价水平，处于近期价格区间的中部，近期成交量没有明确方向。整体情况好坏参半，也许更适合先观察，而不是急于行动。过去的形态并不能保证未来的结果。
估值 — 相对自身历史处于溢价水平
VRTX 目前的市盈率为 30×，高于其自身 5 年平均的 24×，并且大致持平于我们追踪的同类Healthcare公司（28×，53 家）。投资者目前为每一美元盈利付出的价格高于以往。其自由现金流收益率约为 2.9%。它当前的估值倍数大约位于自身过去五年分布的第 75 百分位——处于自身区间的偏高位置。
价格区间 — 处于近期区间的中部
目前价格为 $535.17，位于其近期的支撑位与阻力位之间。过去一年 VRTX 的价格在 $403.16 到 $560.25 之间波动；其历史支撑区在 $522.56 附近，阻力区在 $560.25 附近。它同时位于 50 日和 200 日均线上方，这在历史上通常对应上升趋势。
资金流向 — 方向不明确
VRTX 近期的买卖成交量大致均衡，没有明显的吸筹或派发形态。过去 30 个交易日，上涨日的成交量约为下跌日的 1.4×。
股息与公司概况
VRTX 不派发股息，但在 2025 财年回购了 18.9亿美元 的股票，约占市值的 1.4%。其股数过去一年减少了 1.2%，五年减少了 2.0%。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.